findmyKOL

Jeffrey Matos, MD

Basic profile

New Jersey Institute of Technology

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyClinical Cardiac ElectrophysiologyFocusCardiology
Last active 2021findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2015Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Jeffrey Matos is a Cardiology physician affiliated with New Jersey Institute of Technology. OpenAlex indexes 34 publications with 1,339 citations (h-index 21).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
34publications

Distinct works indexed by OpenAlex.

1,339citations

Total citations across indexed works.

21h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1421 3rd Ave
New York, NY 100281802

Telephone

212-772-6384

Registry record last updated 3 Mar 2010.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    68.4%
    Beta blocker35.2%
    Metoprolol Succinate100%
    Part D27 patients
    Antiarrhythmic17.8%
    Amiodarone Hcl56%Norpace Cr44%
    Part D<11 patients

    + 2 more classes in this area

  • Blood & clotting

    26.5%
    Factor Xa inhibitor26.5%
    Eliquis100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    5.1%
    SGLT2 inhibitor5.1%
    Jardiance100%
    Part D<11 patients
Where care is delivered (Part B), 20210% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”